يعرض 1 - 6 نتائج من 6 نتيجة بحث عن '"Platinum sensitive"', وقت الاستعلام: 0.73s تنقيح النتائج
  1. 1
    تقرير
    Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

    المؤلفون: NRG Oncology

    المصدر: A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04034927Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  2. 2
    تقرير
    Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

    المصدر: Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination With Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05353439Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  3. 3
    تقرير
    Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

    المصدر: A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04550494Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  4. 4
    تقرير
    A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

    المصدر: A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04092270Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  5. 5
    تقرير
    Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

    المصدر: Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung Cancer

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03896503Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
  6. 6
    تقرير
    Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    المصدر: Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

    الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT02627443Test

    View record in ClinicalTrials.gov

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث